Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2026
Addressing the distressing: Pancreatic enzyme replacement therapy mitigates abdominal symptoms and weight loss during chemotherapy for advanced pancreatic cancer: A prospective study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Klassen Pamela N, Kim Christina A, Kasnik Jessica, Sawyer Michael B, Ghosh Sunita, Baracos Vickie, Mazurak Vera C
Аннотация
BACKGROUND: Pancreatic enzyme insufficiency (PEI) contributes to symptom burden and malnutrition in advanced pancreatic cancer (aPC). We aimed to evaluate the impact of pancreatic enzyme replacement therapy (PERT) on symptom burden and weight during chemotherapy.
METHODS: Patients with aPC who were referred to a dietitian for suspected PEI at the Cross Cancer Institute (Edmonton, Canada) were enrolled. Baseline (BL) PEI symptoms were evaluated prior to PERT initiation; dose was optimized by 1 month. PEI symptom severity was assessed with the Pancreatic Enzyme Insufficiency Questionnaire (PEI-Q) at BL, reassessed after 1 and 3 months, and compared between BL and first reassessment. Mean weight change from BL to 1 month (percentage per 30 days) was compared with change from 1 to 3 months. Continuous and categorical variables were compared using paired samples t tests and McNemar test, respectively.
RESULTS: Of 29 patients enrolled, 23 initiated PERT and completed ≥1 symptom reassessment. Median reported PERT dose at reassessment was 200,000 USP lipase units/day (IQR 97,200, 300,000). Improvements in mean severity scores for stomach pain (P = 0.001) bloating (P = 0.049) and stomach noises (P = 0.032) were reported at reassessment, with a trend toward improved appetite (P = 0.053). Prevalence of moderate/severe PEI decreased (11/23 vs 4/23, P = 0.020). Weight loss slowed after 1 month (-4.3 ± 4.8%/30 days [BL to 1 month] vs -0.2 ± 3.9%/30 days, P = 0.033).
CONCLUSION: Patients receiving dietitian-directed PERT showed improved abdominal symptoms and attenuated weight loss after dose optimization, addressing a patient priority for those with aPC.
METHODS: Patients with aPC who were referred to a dietitian for suspected PEI at the Cross Cancer Institute (Edmonton, Canada) were enrolled. Baseline (BL) PEI symptoms were evaluated prior to PERT initiation; dose was optimized by 1 month. PEI symptom severity was assessed with the Pancreatic Enzyme Insufficiency Questionnaire (PEI-Q) at BL, reassessed after 1 and 3 months, and compared between BL and first reassessment. Mean weight change from BL to 1 month (percentage per 30 days) was compared with change from 1 to 3 months. Continuous and categorical variables were compared using paired samples t tests and McNemar test, respectively.
RESULTS: Of 29 patients enrolled, 23 initiated PERT and completed ≥1 symptom reassessment. Median reported PERT dose at reassessment was 200,000 USP lipase units/day (IQR 97,200, 300,000). Improvements in mean severity scores for stomach pain (P = 0.001) bloating (P = 0.049) and stomach noises (P = 0.032) were reported at reassessment, with a trend toward improved appetite (P = 0.053). Prevalence of moderate/severe PEI decreased (11/23 vs 4/23, P = 0.020). Weight loss slowed after 1 month (-4.3 ± 4.8%/30 days [BL to 1 month] vs -0.2 ± 3.9%/30 days, P = 0.033).
CONCLUSION: Patients receiving dietitian-directed PERT showed improved abdominal symptoms and attenuated weight loss after dose optimization, addressing a patient priority for those with aPC.